Get the Stockscreener App
0.3638
3.24%
-0.0122
After Hours:
.38
0.0162
+4.45%
Moleculin Biotech Inc stock is traded at $0.3638, with a volume of 2.52M.
It is down -3.24% in the last 24 hours and down -45.05% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.376
Open:
$0.377
24h Volume:
2.52M
Relative Volume:
0.41
Market Cap:
$11.02M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0238
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-2.99%
1M Performance:
-45.05%
6M Performance:
-71.13%
1Y Performance:
-85.03%
1-Day Range:
$0.36
$0.3823
1-Week Range:
$0.357
$0.423
52-Week Range:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.3638 | 11.55M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock - Investing.com
Moleculin Biotech accelerates recruitment in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial - GlobeNewswire
Moleculin Biotech Expands Global Phase 2B/3 Trial - TipRanks
Moleculin Biotech Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - MarketScreener
Moleculin expands AML trial sites globally, targets 45 patients by Q4 - Investing.com
Moleculin Biotech, Inc. Expands Global Recruitment for MIRACLE Trial in Europe and the US, Aiming for 45 Patients by Q4 2025 - Quiver Quantitative
Global Expansion: Moleculin's MIRACLE Leukemia Trial Reaches 13 Patients, Targeting 45 for Key Data Analysis - Stock Titan
Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment - TipRanks
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - GlobeNewswire
Moleculin Biotech Releases New Corporate Presentation - TipRanks
Moleculin enrolls first EU patients in pivotal AML cancer trial By Investing.com - Investing.com South Africa
Will Moleculin Biotech Inc. Sustain Its Chart BreakoutJuly 2025 Drop Watch & Smart Investment Allocation Tips - beatles.ru
Moleculin enrolls first EU patients in pivotal AML cancer trial - Investing.com
Moleculin doses first EU patient in phase 3 pivotal MIRACLE trial for treatment of Acute Myeloid Leukemia - MarketScreener
First EU Patients Enrolled: Moleculin's Phase 3 MIRACLE Trial Targets Hard-to-Treat Leukemia - Stock Titan
Moleculin Biotech Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Accurate Intraday Trade Tips - beatles.ru
Is Moleculin Biotech Inc. stock a smart retirement pickQuarterly Risk Review & Capital Efficient Trading Techniques - 뉴스영
Moleculin Biotech Completes Promising Annamycin Trial - MSN
Is Moleculin Biotech Inc. in a consolidation phaseShare Buyback & Daily Entry Point Alerts - خودرو بانک
Is Moleculin Biotech Inc. stock a buy or sellPortfolio Value Report & AI Powered Market Entry Strategies - خودرو بانک
Is Moleculin Biotech Inc. stock undervalued right nowInflation Watch & Verified Swing Trading Watchlists - خودرو بانک
What’s the outlook for Moleculin Biotech Inc.’s sectorJuly 2025 Trends & Weekly Top Performers Watchlists - خودرو بانک
Does Moleculin Biotech Inc. align with a passive investing strategyCEO Change & Smart Allocation Stock Tips - خودرو بانک
Backtesting results for Moleculin Biotech Inc. trading strategies2025 Investor Takeaways & Expert Verified Movement Alerts - Newser
Can Moleculin Biotech Inc. expand into new marketsEarnings Beat & Free Daily Entry Point Trade Alerts - خودرو بانک
Moleculin Biotech Inc. stock trend forecastQuarterly Trade Report & Risk Adjusted Buy/Sell Alerts - Newser
Custom watchlist performance reports with Moleculin Biotech Inc.Market Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Long term hold vs stop loss in Moleculin Biotech Inc.Weekly Trend Summary & Low Risk High Win Rate Stock Picks - Newser
Volume spikes in Moleculin Biotech Inc. stock – what they meanJuly 2025 Trends & AI Powered Trade Plan Recommendations - Newser
Why Moleculin Biotech Inc. is moving todayPortfolio Value Report & Low Drawdown Trading Strategies - Newser
Using Bollinger Bands to evaluate Moleculin Biotech Inc.July 2025 Institutional & Real-Time Chart Pattern Alerts - Newser
Will Moleculin Biotech Inc. stock hit new highs in YEARJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - خودرو بانک
Is Moleculin Biotech Inc. showing signs of accumulationTrend Reversal & Verified Trade Idea Suggestions - Newser
Why is Moleculin Biotech Inc. stock going upPortfolio Value Summary & AI Driven Price Forecasts - خودرو بانک
Understanding Moleculin Biotech Inc.’s price movementQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Will Moleculin Biotech Inc. stock recover after recent drop2025 Buyback Activity & Daily Growth Stock Tips - Newser
Will Moleculin Biotech Inc. bounce back from current supportCPI Data & AI Powered Buy and Sell Recommendations - Newser
Aug EndMonth: What’s the outlook for Moleculin Biotech Inc.’s sectorAnalyst Upgrade & Step-by-Step Trade Execution Guides - خودرو بانک
Fed Watch: Is Moleculin Biotech Inc. forming a breakout patternChart Signals & Consistent Income Trade Recommendations - خودرو بانک
Is Moleculin Biotech Inc. stock a hidden gem2025 Risk Factors & Precise Trade Entry Recommendations - خودرو بانک
Analyzing drawdowns of Moleculin Biotech Inc. with statistical tools2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
Is Moleculin Biotech Inc. likely to announce a buybackWeekly Stock Summary & Free Safe Capital Growth Stock Tips - خودرو بانک
Is Moleculin Biotech Inc. building a consolidation base2025 Support & Resistance & Long-Term Growth Stock Strategies - Newser
Trend analysis for Moleculin Biotech Inc. this weekPortfolio Performance Summary & Low Risk Entry Point Guides - Newser
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):